LongTermGevity Inc. ("LTG") is addressing chronic pain and neurological disorders with psychedelic therapeutics. LTG's robust IP portfolio includes a groundbreaking technology designed to facilitate the controlled delivery of psilocin on the skin to directly target an injury site. LTG's controlled dosage allows patients to receive the medical benefit of psilocybin without undesired effects.